“Having a drug that [patients] can be confident in that will be highly effective as well as well tolerated is a great advantage," said Edward Hook, MD.

If approved, this UC indication would add to pediatric indications of ustekinumab for psoriasis and active psoriatic arthritis.

A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.

In this Q&A, nurse practitioner Tracey Gaslin, PhD, discusses tick bites in pediatric patients, from how to prevent a bite to what to do after a bite, and highlights resources available from the Fight...

IDSA’s new GAS pharyngitis guidance emphasizes selective testing using clinical scoring to reduce overtreatment and antibiotic misuse.

Hands-on menstruation education fosters confidence, reduces stigma, and equips adolescents with practical skills for menstrual health.

A quick look into some of the top sessions occurring at the 2025 American Academy of Pediatrics National Conference & Exhibition, being held from September 26-30, 2025, in Denver, Colorado.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from August 2025.

The AAP recommends all children aged 6 to 23 months receive a COVID-19 vaccine, as this group is the highest risk for severe infection.

If approved, vatiquinone would have been the first therapy approved for pediatric patients with FA.